Interleukin-6 (IL-6) receptor antibody therapy to malignant pleural mesothelioma

白细胞介素-6 （IL-6）与类风湿关节炎有关。Tocilizumab （Actemra：一种人源化抗il - 6r抗体）用于类风湿性关节炎治疗。我们研究了托珠单抗对恶性胸膜间皮瘤的影响。托珠单抗抑制恶性胸膜间皮瘤细胞生长，减少10-25%。我们比较培美曲塞、顺铂和托珠单抗的联合疗效。培美曲塞、顺铂和托珠单抗联合使用比其他任何两种药物联合使用更有效。我们已经确认了MEK抑制剂的作用。我们检查托珠单抗与MEK抑制剂联合使用的效果。tocilizumab和MEK抑制剂联合使用比单独给药MEK抑制剂更能抑制恶性胸膜间皮瘤细胞的生长。Tocilizumab将phoho - stat3表达降低至1/3-1/5。tocilizumab与MEK抑制剂联合使用更能降低phosh - stat3的表达。

Interleukin-6 (IL-6) is associated with rheumatoid arthritis. Tocilizumab (Actemra : a humanized anti-IL-6R antibody) is used for rheumatoid arthritis therapy. We investigated the effect of tocilizumab to malignant pleural mesothelioma. Tocilizumab suppressed malignant pleural mesothelioma cell growth and reductions were 10-25%. We compared the combination effect of pemetrexed, cisplatin and tocilizumab. The combination of pemetrexed, cisplatin and tocilizumab was more effective than any other two drugs combinations. We have already conformed the effect of MEK inhibitor. We checked the combination effect of tocilizumab and MEK inhibitor. The combination of tocilizumab and MEK inhibitor suppressed malignant pleural mesothelioma cell growth more than a single administration of MEK inhibitor. Tocilizumab reduced the phosho-Stat3 expression to 1/3-1/5. The combination of tocilizumab and MEK inhibitor reduced more the phosho-Stat3 expression.